ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
Decoding the tumor immune landscape: emerging TIL subsets as prognostic biomarkers and therapeutic targets.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor -infiltrating lymphocytes (TILs) play a pivotal role in cancer immunity, with CD3 + T cells and CD8 + cytotoxic T cells historically regarded as key prognostic markers. Other TIL subsets are CD4 + T helper cells, regulatory T cells (Tregs), tissue-resident memory T cells (TRM cells), and non-traditional T cell populations like γδ T cells and innate-like T cells. These subsets have diverse roles which influence the disease duration and immunotherapy mechanism, from immune evasion to tumor suppression. TRM cells which are recognized by the expression of CD103 and CD69 are linked with better survival and enhance tumor management, while Tregs function mainly in the tumor microenvironment (TME). Additionally, γδ T cells have strong anti-cancer activity. Developments in single-cell sequencing and spatial transcriptomics have improved the understanding of TIL heterogeneity and their functional states, enhancing their prognostic and therapeutic significance. Understanding how different expanded TIL subgroups impact treatment response helps to recognize new biomarkers and therapeutic targets. This review investigates functions of TIL populations beyond the traditional markers like CD3 and CD8 across different cancers while concentrating on predictive outcomes in immunotherapy.
Indexed as
Identifiers
41579172What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.